Dear editor,

We were very pleased to see the article on the impact of migraines on workplace productivity.

However, we noticed a small error at the end regarding the source. The study in question was not part of a specific Topamax study program and was non-branded. Ortho-McNeil Neurologics sponsored the study, and markets the FDA-approved product, Topamax, for migraine prevention.

It is a small error, but we felt obliged to ensure the correct information was provided.

Thank you and best regards,

Kara Russell

Senior Director

Ortho-McNeil Neurologics Communications

Titusville, N.J.